Business Context and Reporting Period
This Form 6-K filing by Innate Pharma S.A., a foreign private issuer, covers the month of March 2023. The report, dated March 23, 2023, incorporates by reference a press release (Exhibit 99.1) and is signed by Mondher Mahjoubi, Chairman of the Executive Board and CEO.
Key Financial Metrics
The filing text provided does not contain specific financial data. No values for revenue, profit, cash flow, margins, debt, or liquidity are disclosed in this document.
Material Changes
The filing text does not provide information regarding material changes versus prior comparable periods.
Guidance, Outlook, and Risks
The filing text does not include management commentary, guidance, outlook, risks, contingencies, or details on unusual items. The document serves primarily as a cover sheet incorporating an external press release.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) referenced in this filing for specific operational or clinical updates.
- Verify the company's latest financial position in the most recent Form 20-F or quarterly reports, as this 6-K contains no financial tables.
- Confirm the status of the registration statement on Form F-3 (File No. 333-252074) into which this report is incorporated.